Immunodiagnostic Systems Holdings plc announced the launch of four new i-Tracker® assays designed to run on its automated IDS-iSYS analyser. These assays were developed by partner Theradiag SA (Theradiag) and address the rapidly growing market of biologics drug monitoring. The four i-Tracker® assays: i-Tracker® Infliximab, i-Tracker® Anti-Infliximab, i-Tracker® Adalimumab and i-Tracker® Anti-Adalimumab were previously launched on the 'i-Track10®' analyser, an instrument manufactured by IDS for Theradiag. In the six months since the Theradiag launch, the assays have undergone validation on the IDS-iSYS analyser and are now available for use on the installed base of IDS-iSYS analysers in Europe and other territories which accept a CE mark accreditation.